Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' Net Income towards Common Stockholders fell 2972.65% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.2 million, marking a year-over-year decrease of 4578.83%. This contributed to the annual value of -$160.9 million for FY2024, which is 5953.27% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Net Income towards Common Stockholders of -$56.9 million as of Q3 2025, which was down 2972.65% from -$54.7 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders peaked at -$7.6 million during Q2 2021, and registered a low of -$56.9 million during Q3 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$28.7 million (2023), whereas its average is -$31.6 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Net Income towards Common Stockholders skyrocketed by 6007.94% in 2023 and then tumbled by 32748.63% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$25.1 million in 2021, then fell by 9.15% to -$27.4 million in 2022, then decreased by 17.91% to -$32.3 million in 2023, then tumbled by 53.86% to -$49.7 million in 2024, then decreased by 14.51% to -$56.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$56.9 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$48.0 million for Q1 2025.